Delcath(US:DCTH)2024-08-05 20:12Financial Performance - Total revenue for Q2 2024 was $7.8 million, a significant increase from $0.5 million in Q2 2023, representing a 1460% year-over-year growth[3] - The company reported a net loss of $13.7 million for Q2 2024, compared to a net loss of $7.2 million in Q2 2023[11] - Total liabilities as of June 30, 2024, were $29.7 million, an increase from $22.8 million at the end of 2023[9] Revenue Sources - Revenue breakdown includes $6.6 million from HEPZATO KIT sales in the U.S. and $1.2 million from CHEMOSAT sales in Europe[2] Expenses - Research and development expenses for Q2 2024 were $3.4 million, slightly down from $3.6 million in the same period last year[3] - Selling, general, and administrative expenses increased to $6.8 million in Q2 2024 from $4.8 million in Q2 2023, reflecting higher marketing and personnel costs[3] Operational Developments - Three new HEPZATO KIT treating centers were activated in the U.S. during Q2, bringing the total to eight active centers[2] - The company received New Technology Add-on Payment status for HEPZATO from CMS on August 1, 2024, which provides additional payments to hospitals for inpatient treatments[2] - The pivotal Phase 3 FOCUS study results for HEPZATO KIT were published in the Annals of Surgical Oncology, with a poster presentation scheduled for the upcoming ESMO conference in September 2024[2] Cash Position - The company ended Q2 2024 with cash and investments totaling $19.9 million[4]